A Shot at Ending HIV: The Promise of Lenacapavir

HIV remains a global health crisis, infecting more than 1 million people annually. Although research has advanced to treat people who become infected, a vaccine to protect people from infection remains elusive. However, a new injectable drug from Gilead Sciences, lenacapavir, is reshaping the fight against the virus. Unlike pre-exposure prophylaxis (PrEP) pills, which must be taken daily, a single shot of lenacapavir protects against HIV for six months.

Hope for the Future

Gene Therapy at QPS

Encouraging Preclinical Results Show Gene Therapy Reduces Seizures

California-based Capsida Biotherapeutics has reported promising preclinical results for CAP-002, its gene therapy for developmental and epileptic encephalopathy (DEE) caused by mutations in the syntaxin-binding protein 1 (STXBP1) gene. The research demonstrated the therapy’s ability to reduce seizures, improve cognitive and motor function and restore brain activity in animal studies, signaling hope for patients with this rare and severe condition.

Addressing a Devastating Disease

The Ultimate Guide to Gene Therapy